biostudies-literatureBrown TTNIAID NIH HHS983-986https://www.ebi.ac.uk/biostudies/studies/S-EPMC12249367biostudies-literatureUnknown81(5)In a randomized clinical trial, pre-exposure prophylaxis (PrEP) with long-acting cabotegravir (CAB-LA) had a better bone safety profile than tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) over 105 weeks. For individuals with low bone mineral density or other fracture risk factors, CAB-LA PrEP should be considered over TDF-based PrEP. Clinical Trials Registration.  clinicaltrials.gov (NCT02720094).Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaBone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083.PMC12249367UM1 AI069424UM1 AI068613UM1 AI068636UM1 AI068617UM1 AI068619U01 AI069476UM1 AI069476Rinehart AROyedele TLandovitz RJHanscom BVasconcelos RWarsi MMcCauley MRooney JFArao RFSullivan PABrown TTGrinsztejn BPhanuphak NfalseBone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083.In a randomized clinical trial, pre-exposure prophylaxis (PrEP) with long-acting cabotegravir (CAB-LA) had a better bone safety profile than tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) over 105 weeks. For individuals with low bone mineral density or other fracture risk factors, CAB-LA PrEP should be considered over TDF-based PrEP. Clinical Trials Registration.  clinicaltrials.gov (NCT02720094).2025-01-01T00:00:00Z2025 Dec2026-06-06T17:44:05.241Z2026-06-03T03:10:34.902ZS-EPMC122493674059045210.1093/cid/ciaf221